DEMOS - Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The purpose of this study is to characterize the real-life experience of patients with moderate/severe psoriasis receiving deucravacitinib treatment, in terms of efficacy, safety, and health-related quality of life (HRQoL) in Italy
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Participants have initiated treatment with deucravacitinib monotherapy 4 to 8 weeks earlier according to clinical practice and to reimbursement criteria determined by National Drug Agency in Italy (AIFA)
• Patients have moderate to severe plaque psoriasis
• Patients have signed informed consent form (ICF)
Locations
Other Locations
Italy
Azienda Ospedaliera Universitaria Integrata Di Verona
RECRUITING
Verona
Contact Information
Primary
BMS Study Connect Contact Center www.BMSStudyConnect.com
Clinical.Trials@bms.com
855-907-3286
Backup
First line of the email MUST contain NCT # and Site #
Time Frame
Start Date: 2025-08-05
Estimated Completion Date: 2027-08-05
Participants
Target number of participants: 200
Treatments
Cohort 1
Participants with moderate/severe psoriasis receiving deucravacitinib
Related Therapeutic Areas
Sponsors
Leads: Bristol-Myers Squibb